...
首页> 外文期刊>Current medical research and opinion >Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: Escitalopram vs paroxetine
【24h】

Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: Escitalopram vs paroxetine

机译:基线焦虑对重度抑郁症患者SSRI治疗结果的影响:依西酞普兰vs帕罗西汀

获取原文
获取原文并翻译 | 示例

摘要

To investigate if treatment outcome for severely depressed patients depends on their baseline level of anxiety. Patients with a primary diagnosis of severe major depressive disorder (nCombining double low line459) were randomised to 24 weeks of double-blind treatment with escitalopram (20mg) or paroxetine (40mg). Post hoc analyses of efficacy in patients with a baseline HAM-A total score ≤20 (nCombining double low line171) or >20 (nCombining double low line280) were based on analysis of covariance (ANCOVA) (ITT, LOCF). At week 24, the mean change from baseline in MADRS total scores was-24.2 for escitalopram-treated patients (nCombining double low line141) and-21.5 for paroxetine-treated patients (nCombining double low line139) (p<0.05) in high baseline anxiety patients and the mean change from baseline in HAM-A total score was-17.4 (escitalopram) and-15.1 (paroxetine) (p<0.05). When examining the proportion of complete remitters (CGI-SCombining double low line1) after 24 weeks of treatment, there was an increasing treatment difference as a function of baseline HAM-A total score in favour of escitalopram (ITT, LOCF). There was no treatment difference in the low baseline anxiety group. Significantly more patients (p<0.01) withdrew from the paroxetine group (31) than from the escitalopram group (17), partly as the result of significantly more withdrawals due to AEs (p<0.05). Incidence of AEs and withdrawals were not related to baseline anxiety and there were no significant differences in the incidence of individual AEs with escitalopram compared to paroxetine. The post hoc nature of these analyses, the absence of placebo control group, and the requirement that patients should be suffering from severe depression, limit the generalisability of the results. Patients with severe depression together with comorbid anxiety symptoms responded significantly better to treatment with escitalopram 20mg compared with paroxetine 40mg. Contrary to paroxetine, escitalopram maintained its efficacy with increasing baseline anxiety levels.
机译:调查严重抑郁症患者的治疗结果是否取决于其基线焦虑水平。初步诊断为严重重度抑郁症的患者(nCombining双低线459)被随机分配到艾司西酞普兰(20mg)或帕罗西汀(40mg)双盲治疗的24周内。基于协方差分析(ANCOVA)(ITT,LOCF),对基线HAM-A总得分≤20(nCombining双低线171)或> 20(nCombining双低线280)的患者进行事后分析。在第24周时,依地西酞普兰治疗的患者(nCombining双低线141)与MADRS总评分相对于基线的平均变化为-24.2,帕罗西汀治疗的患者(ncombining双低线139)为-21.5(p <0.05) HAM-A总评分与基线相比的平均变化为-17.4(依他普仑)和-15.1(帕罗西汀)(p <0.05)。在治疗24周后检查完全缓解者的比例(CGI-SCombining双低线1)时,作为基线HAM-A总分的函数,治疗差异有所增加,而依他普仑(ITT,LOCF)偏高。低基线焦虑症组没有治疗差异。帕罗西汀组(31)退出治疗的患者(p <0.01)比依西酞普兰组(17)显着增加,部分原因是由于AE引起的撤药明显更多(p <0.05)。 AEs和戒断的发生与基线焦虑无关,与帕罗西汀相比,依西酞普兰的个体AE发生率无显着差异。这些分析的事后性质,缺乏安慰剂对照组,以及患者应患有严重抑郁症的要求限制了结果的推广性。与帕罗西汀40mg相比,重度抑郁症并发焦虑症状的患者对20mg依他普仑治疗的反应明显更好。与帕罗西汀相反,依他普仑通过增加基线焦虑水平来维持其疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号